Inhalation: Pulmicort (AstraZeneca)
Pulmicort®, inhaled anti-inflammatory glucocorticosteroid for asthma maintenance therapy
- Sales for all forms US$570 m (1st 9 months 2001)
Replacing CFC (greenhouse gas) with HFA in metered dose inhaler (MDI)
SKP responsible for all pre-clinical & clinical development
US$2m upfront out of total US$10m milestones; future royalties